These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 19523982)

  • 1. Sensitive detection of the K103N non-nucleoside reverse transcriptase inhibitor resistance mutation in treatment-naïve HIV-1 infected individuals by rolling circle amplification.
    Wang B; Dwyer DE; Chew CB; Kol C; He ZP; Joshi H; Steain MC; Cunningham AL; Saksena NK
    J Virol Methods; 2009 Oct; 161(1):128-35. PubMed ID: 19523982
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Prevalence of drug resistance mutations among antiretroviral drug-naive HIV-1-infected patients in China].
    Si XF; Huang HL; Wei M; Guan Q; Song YH; Ma PF; Quan Y; Xing H; Shao YM
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2004 Dec; 18(4):308-11. PubMed ID: 15650776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of minor variants of HIV strains at reverse transcriptase position 103 in therapy-naïve patients and their impact on the virological failure.
    Balduin M; Oette M; Däumer MP; Hoffmann D; Pfister HJ; Kaiser R
    J Clin Virol; 2009 May; 45(1):34-8. PubMed ID: 19375978
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug resistant mutations detected by genotypic drug resistance testing in patients failing therapy in clade C HIV-1 infected individuals from India.
    Kandathil AJ; Kannangai R; Verghese VP; Pulimood SA; Rupali P; Sridharan G; Grant P; Pillay D; Abraham OC
    Indian J Med Microbiol; 2009; 27(3):231-6. PubMed ID: 19584504
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A sensitive in-house RT-PCR genotyping system for combined detection of plasma HIV-1 and assessment of drug resistance.
    Steegen K; Demecheleer E; De Cabooter N; Nges D; Temmerman M; Ndumbe P; Mandaliya K; Plum J; Verhofstede C
    J Virol Methods; 2006 May; 133(2):137-45. PubMed ID: 16375980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impacts of current antiretroviral therapy regimens on Chinese AIDS patients and their implications for HIV-1 drug resistance mutation.
    Zhang M; Han XX; Cui WG; Jia MH; Meng XD; Xing AH; Wu YH; Yang YY; Lu CM; Hu QH; Dai D; Zhang ZN; Shang H
    Jpn J Infect Dis; 2008 Sep; 61(5):361-5. PubMed ID: 18806342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary drug resistance in antiretroviral-naïve injection drug users.
    Tossonian HK; Raffa JD; Grebely J; Viljoen M; Mead A; Khara M; McLean M; Krishnamurthy A; DeVlaming S; Conway B
    Int J Infect Dis; 2009 Sep; 13(5):577-83. PubMed ID: 19111493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV-1 resistance to first- and second-generation non-nucleoside reverse transcriptase inhibitors.
    Ghosn J; Chaix ML; Delaugerre C
    AIDS Rev; 2009; 11(3):165-73. PubMed ID: 19654858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes.
    Simen BB; Simons JF; Hullsiek KH; Novak RM; Macarthur RD; Baxter JD; Huang C; Lubeski C; Turenchalk GS; Braverman MS; Desany B; Rothberg JM; Egholm M; Kozal MJ;
    J Infect Dis; 2009 Mar; 199(5):693-701. PubMed ID: 19210162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Updated prevalence of genotypic resistance among HIV-1 positive patients naïve to antiretroviral therapy: a single center analysis.
    Lapadula G; Izzo I; Gargiulo F; Paraninfo G; Castelnuovo F; Quiros-Roldan E; Cologni G; Ceresoli F; Manca N; Carosi G; Torti C
    J Med Virol; 2008 May; 80(5):747-53. PubMed ID: 18360912
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiretroviral drug resistance surveillance among drug-naive HIV-1-infected individuals in Gauteng Province, South Africa in 2002 and 2004.
    Pillay V; Ledwaba J; Hunt G; Rakgotho M; Singh B; Makubalo L; Bennett DE; Puren A; Morris L
    Antivir Ther; 2008; 13 Suppl 2():101-7. PubMed ID: 18575198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selection and persistence of non-nucleoside reverse transcriptase inhibitor-resistant HIV-1 in patients starting and stopping non-nucleoside therapy.
    Palmer S; Boltz V; Maldarelli F; Kearney M; Halvas EK; Rock D; Falloon J; Davey RT; Dewar RL; Metcalf JA; Mellors JW; Coffin JM
    AIDS; 2006 Mar; 20(5):701-10. PubMed ID: 16514300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resistance profile of the new nucleoside reverse transcriptase inhibitor apricitabine.
    Cahn P; Wainberg MA
    J Antimicrob Chemother; 2010 Feb; 65(2):213-7. PubMed ID: 20007333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evolution of genetic diversity and drug resistance mutations in HIV-1 among untreated patients from Mali between 2005 and 2006.
    Derache A; Maiga AI; Traore O; Akonde A; Cisse M; Jarrousse B; Koita V; Diarra B; Carcelain G; Barin F; Pizzocolo C; Pizarro L; Katlama C; Calvez V; Marcelin AG
    J Antimicrob Chemother; 2008 Sep; 62(3):456-63. PubMed ID: 18556706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nucleoside reverse transcriptase inhibitor-sparing regimen (nonnucleoside reverse transcriptase inhibitor + protease inhibitor) was more likely associated with resistance comparing to nonnucleoside reverse transcriptase inhibitor or protease inhibitor + nucleoside reverse transcriptase inhibitor in the randomized ANRS 121 trial.
    Soulié C; Assoumou L; Ghosn J; Duvivier C; Peytavin G; Ait-Arkoub Z; Molina JM; Costagliola D; Katlama C; Calvez V; Marcelin AG
    AIDS; 2009 Jul; 23(12):1605-8. PubMed ID: 19487903
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between mutations in HIV-1 RNase H domain and nucleoside reverse transcriptase inhibitors resistance mutations in naïve and pre-treated HIV infected patients.
    Roquebert B; Wirden M; Simon A; Deval J; Katlama C; Calvez V; Marcelin AG
    J Med Virol; 2007 Mar; 79(3):207-11. PubMed ID: 17245724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV-1 drug resistance mutations in children who failed non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy.
    Sungkanuparph S; Apiwattanakul N; Thitithanyanont A; Chantratita W; Sirinavin S
    Southeast Asian J Trop Med Public Health; 2009 Jan; 40(1):83-8. PubMed ID: 19323038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Profile of drug resistance mutations among HIV-1-infected Tunisian subjects failing antiretroviral therapy.
    Jlizi A; Ben Ammar El Gaaied A; Slim A; Tebourski F; Ben Mamou M; Ben Chaabane T; Letaief-Omezzine A; Chakroun M; Garbouj M; Ben Rejeb S
    Arch Virol; 2008; 153(6):1103-8. PubMed ID: 18483694
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selection of drug-resistant HIV-1 during the early phase of viral decay is uncommon in treatment-naïve patients initiated on a three- or four-drug antiretroviral regimen including lamivudine.
    Bergroth T; Ekici H; Gisslén M; Loes SK; Goh LE; Freedman A; Lampe F; Johnson MA; Sönnerborg A
    J Med Virol; 2009 Jan; 81(1):1-8. PubMed ID: 19031460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of the diversity of the HIV-1 pol gene and drug resistance associated changes among drug-naïve patients in Burkina Faso.
    Tebit DM; Sangaré L; Tiba F; Saydou Y; Makamtse A; Somlare H; Bado G; Kouldiaty BG; Zabsonre I; Yameogo SL; Sathiandee K; Drabo JY; Kräusslich HG
    J Med Virol; 2009 Oct; 81(10):1691-701. PubMed ID: 19697403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.